News >

Ahn Recaps Advances and Challenges in Gastric/GEJ Cancers

Caroline Seymour
Published: Thursday, Jun 07, 2018

Daniel H. Ahn, DO

Daniel H. Ahn, DO

Although research in the field of gastric and gastroesophageal (GEJ) cancers is focusing on targeting CLDN18.2 and VEGF, Daniel Ahn, DO, explained that the area that has piqued everyone’s interest is immunotherapy.

State of the Science Summit™, Ahn discussed advances and challenges with targeted and immune-based therapies in the treatment of patients with gastric and GEJ cancer.

OncLive: What advancements have we seen in gastric/GEJ cancers?

Ahn: A lot has changed in the way we treat gastric and GEJ cancers. We've had a lot of recent updates, in both the perioperative setting with the FLOT4 data and the metastatic setting with RAINFALL and JACOB. There are a lot of new emerging therapies specifically looking at targeting CLDN18.2, as well as looking at T-cell bispecific antibodies.

I would say there is a role for immune checkpoint inhibitors. The question is, “In what role of therapy?” Right now, immune checkpoint inhibitors are a relevant treatment in the refractory setting, specifically in PD-L1–positive patients in treating metastatic gastric or GEJ cancers. In patients who are PD-L1 negative or [low PD-L1 expression], we know that there is activity for pembrolizumab, but [there are] concerns for toxicities. There are also 2 negative phase III studies, so I would be very hesitant [to use it] right now, though it was still considered as a treatment option. I wouldn't move it into the second-line or earlier-stage setting. Other clinical trials are currently investigating that.

What targeted therapies are being investigated?

There are 3 relevant targets right now, including VEGF. There are positive data with using ramucirumab in the refractory setting. However, the positive data from the RAINFALL study did not manifest into clinical significance. The difference was about 0.3 months. In terms of its role in the first-line setting, ramucirumab should be avoided and primarily [used] in the refractory setting, so second-line setting or beyond—depending on what patients received in the first-line setting. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x